Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Prashanth Sirigere Manjunath

Interventional Pain Medicine Kingman, AZ Medical Doctor

NPI 1629227616 CMS profile 119454

3801 Santa Rosa Dr, Kingman, AZ 86401

Open in the dashboard

General payments

$6,943

62 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Prashanth Sirigere Manjunath of Kingman, AZ is reported in the CMS Open Payments database as having received $6,943 across 62 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $104 1
2024 General $1,600 1
2023 General $65 1
2022 General $174 4
2021 General $3,688 22
2020 General $193 10
2019 General $1,119 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Prashanth Sirigere Manjunath
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Prashanth Sirigere Manjunath were reported at $104. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Prashanth Sirigere Manjunath Interventional Pain Medicine median Middle half National median
2019 $1,119 $684 $216–$2,079 $163
2020 $193 $382 $122–$1,109 $114
2021 $3,688 $552 $167–$1,554 $132
2022 $174 $605 $187–$1,924 $149
2023 $65 $671 $195–$1,915 $160
2024 $1,600 $684 $206–$1,837 $164
2025 $104 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biohaven Pharmaceuticals, Inc. $3,320 6 payments
  2. Joline Medical Inc $1,600 1 payment
  3. Nevro Corp. $1,299 24 payments
  4. AbbVie, Inc. $237 11 payments
  5. Boston Scientific Corporation $104 1 payment
  6. Allergan Inc. $86 4 payments
  7. SPR Therapeutics, Inc $65 1 payment
  8. Biodelivery Sciences International, Inc. $56 4 payments
  9. Stimwave Technologies Incorporated $31 1 payment
  10. Pfizer Inc. $30 2 payments
  11. Other $115 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,250 3 payments
  2. Travel and Lodging $2,475 6 payments
  3. Food and Beverage $1,218 53 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $3,320 6 payments
  2. Joline Kyphopasty System Allevo $1,600 1 payment
  3. Senza Spinal Cord Stimulation System $1,094 21 payments
  4. Omnia $205 3 payments
  5. UBRELVY Neuroscience $195 9 payments
  6. General - Pain Management $104 1 payment
  7. UBRELVY Neuroscience $86 4 payments
  8. SPRINT PNS System $65 1 payment
  9. BELBUCA $46 3 payments
  10. QULIPTA $41 2 payments
  11. Other $263 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,119

Median for Pain Management: 951

Drug cost

$23,882

Median for Pain Management: $26,034

Branded share of claims

23.1%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 32 $4,398
Lidocaine Generic 45 $3,401
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 176 $3,172
Diclofenac Sodium Generic 88 $1,963
Duloxetine Hcl Generic 92 $1,797
Gabapentin Generic 148 $1,578
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 70 $1,543
Pregabalin Generic 45 $958
Celecoxib Generic 29 $804
Tizanidine Hcl Generic 84 $678

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$57,666

Medicare's payments for the services billed

Medicare patients

165

Average age 73

Services billed

861

102 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Depression 35%
Ischemic heart disease 32%
COPD 28%
Chronic kidney disease 25%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record